• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

BYL-719

CAS No. 1217486-61-7

BYL-719 ( Alpelisib )

产品货号. M10815 CAS No. 1217486-61-7

Alpelisib (BYL-719) 是一种有效的选择性 PI3Kα 抑制剂,在无细胞测定中 IC50 为 5 nM,对 PI3Kβ/γ/δ 的影响极小。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥347 有现货
5MG ¥561 有现货
10MG ¥931 有现货
25MG ¥1628 有现货
50MG ¥2585 有现货
100MG ¥3492 有现货
200MG ¥4995 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥657 有现货

生物学信息

  • 产品名称
    BYL-719
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Alpelisib (BYL-719) 是一种有效的选择性 PI3Kα 抑制剂,在无细胞测定中 IC50 为 5 nM,对 PI3Kβ/γ/δ 的影响极小。
  • 产品描述
    Alpelisib (BYL-719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.(In Vitro):Alpelisib (BYL-719) potently inhibits the 2 most common PIK3CA somatic mutations (H1047R, E545K; IC50s~4 nM). Alpelisib potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74±15 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (≥15-fold compared with PI3Kα).Alpelisib (BYL-719, 0-50 μM; 72 hours) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner.Alpelisib (BYL-719) significantly alters the distribution of cell cycle phases. Alpelisib (BYL-719, 25 μM; 18 hours) induces a cell cycle arrest in the G0/G1 phase of human and murine osteosarcoma cell lines.(In Vivo):Alpelisib (BYL-719) (12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice; oral administration; daily) significantly reduces tumor volumes and deposition of ectopic bone matrix.Alpelisib has moderate terminal elimination half-life (t1/2=2.9±0.2 h) for rat (1 mg/kg, iv) .
  • 体外实验
    ——
  • 体内实验
    Animal Model:A 5-week-old female Rj:NMRI-nude mice withhuman HOS-MNNG osteosarcoma cells; A 5-week-old male C57Bl/6J mice with mouse MOS-J osteosarcoma cells Dosage:12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice Administration:Oral administration; daily; 22 or 29 days for C57Bl/6J mice or Rj:NMRI-nude mice Result:Significantly reduced tumor volumes and simultaneously reduced tumor growth.Animal Model:Female Sprague Dawley rats Dosage:1 mg/kg (Pharmacokinetic Analysis)Administration:I.V.Result:t1/2=2.9±0.2 hours.
  • 同义词
    Alpelisib
  • 通路
    PI3K/Akt/mTOR signaling
  • 靶点
    PI3K
  • 受体
    PI3Kα
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1217486-61-7
  • 分子量
    441.47
  • 分子式
    C19H22F3N5O2S
  • 纯度
    >98% (HPLC)
  • 溶解度
    Ethanol: 2 mg/mL (4.53 mM); DMSO: 88 mg/mL (199.33 mM)
  • SMILES
    O=C(N1[C@H](C(N)=O)CCC1)NC2=NC(C)=C(C3=CC(C(C)(C)C(F)(F)F)=NC=C3)S2
  • 化学全称
    (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Dejan Juric, et al. 2012, AACR 103rd Annual Meeting. Abst CT-0
产品手册
关联产品
  • TGR-1202 R-enantiome...

    TGR-1202 R-对映体是 TGR-1202 (Umbralisib) 活性较低的对映体,TGR-1202 是一种有效的、选择性的、口服的 PI3Kδ 抑制剂,IC50 为 22 nM。

  • GSK1016790A

    GSK1016790A (GSK101) 是一种新型、有效的 TRPV4(瞬时受体电位香草酸 4)激活剂,在脉络丛上皮细胞中的 EC50 为 34 nM。

  • Duvelisib (R enantio...

    Duvelisib R 对映体是 Duvelisib 的活性较低的对映体。 Duvelisib 是一种 PI3K 抑制剂。